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Gene mutationAbstract Background: There is increasing recognition of genetic deﬁciencies underlying pulmon-
ary embolism in some individuals, particularly those with early onset of disease, unusual sites of
venous thrombosis and recurrent disease. The aim of this work is to study the role of mutation
of factor V Leiden, prothrombin (factor II) G20210A and MTHFR C677T genes in patients with
pulmonary embolism.
Patients and methods: Thirty-one patients with pulmonary embolism were investigated for gene
mutation. The genotyping of factor V Leiden, prothrombin G20210A, and methylenetetrahydrof-
olate reductase C677T was performed via real time polymerase chain reaction, using the ﬂuores-
cence melting curve detection analysis.
Results: Twenty-two patients out of 31 (71% of patients) showed factor V Leiden mutation and
15 patients out of 31 (48.4% of patients) showed mutation in MTHFR C677T gene, while pro-
thrombin 20210A gene mutation presented in 5 patients (16.1% of patients). Nine patients (29%
of patients) presented with recurrent DVT and 38.7% of patients showed recurrent pulmonary
embolism. Also, 17 patients (54.8% of patients) presented with other thromboses in addition to pul-
monary embolism. Thirteen patients (41.9%) showed double gene mutation and only one patient
presented with mutations in the three studied genes. Those patients showed a signiﬁcant difference
in the occurrence of other thromboses in the body and signiﬁcant increase in the recurrence of
pulmonary embolism.
1040 G. Elassal et al.Conclusion: Gene mutation especially factor V Leiden mutation is very important to be consid-
ered in young patients presented with venous thrombo-embolism, patients with thrombosis in
unusual sites or patients with recurrent thrombo-embolic manifestations.
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Pulmonary embolism (PE) is a common and sometimes a fatal
disease. Mortality from pulmonary embolism can be reduced
by prompt diagnosis and adequate treatment. Unfortunately,
the clinical presentation of PE is variable and nonspeciﬁc,
leading to difﬁculty in accurate diagnosis.
Pulmonary thromboembolic disease refers to the condition
in which blood clot(s) (thrombus or multiple thrombi) migrate
from the systemic circulation to the pulmonary vasculature.
Most of these blood clots arise from the ‘‘deep veins’’ of the
lower and upper extremities (deep venous thrombosis, DVT).
From the clinical standpoint, DVT and pulmonary embolism
can be considered a continuum of the same disease, and the
two terms are often collectively referred to as venous thrombo-
embolism (VTE) [1].
In the last decades several hereditary coagulation abnor-
malities, including antithrombin and protein C and protein S
defects, have been identiﬁed that predispose patients to venous
thromboembolism [2]. Recently, a mutation in the factor V
gene and a mutation in the prothrombin gene were identiﬁed
and related to an increased risk of venous thromboembolism.
Combined, these two mutations can be identiﬁed in approxi-
mately 25% of patients with venous thromboembolic disorders
[3].
The most common inherited or genetic risk factor for VTE
is factor V Leiden (FVL) gene mutation which is a common
polymorphism in FV. The ﬁrst reference to FVL is in a letter
to the journal Nature by Bertina and colleagues from the
University of Leiden in the Netherlands [4]. A point mutation
in the factor V gene that causes a missense mutation in the pro-
tein (Arg506Gln, factor V Leiden) renders the molecule less
susceptible to inactivation by its naturally occurring inhibitor,
activated protein C (APC). As a result, a single inactivation
site of FV by APC is altered, causing thrombophilia and lead-
ing to intravascular coagulation disorders [5]. The mutation is
found in 3–7% of the healthy Caucasian population [6]. It is
associated with approximately a three-to 10-fold increased risk
of VTE in persons who have inherited heterozygous form of
the mutation, and approximately an 80-fold risk in persons
who show homozygous inheritance [7].
Prothrombin (factor II) is the precursor of thrombin, the
end product of the coagulation cascade. It is a vitamin
K-dependent protein which is synthesized in the liver and cir-
culates with a half-life of approximately three to ﬁve days.
Vitamin K acts as a cofactor for posttranslational gamma-
carboxylation of prothrombin which is required for functional
activity.
G20210A mutation in the prothrombin gene (PTM) was
ﬁrst discovered by Poort et al. [8]. The mutation causes an
increase in mRNA production due to the transitions among
guanine–adenine nucleotides in 20210 position, leading toprothrombin increase and, as a result, in thromboembolic dis-
ease risk [9].
A mildly elevated homocysteine (Hcy) level is generally
accepted as a risk factor for atherosclerosis & thrombotic
tendency [10]. Hyperhomocysteinemia may result from
inherited defects in the controlling enzymes of Hcy metabo-
lism. Methylenetetrahydrofolate reductase (MTHFR) plays
a role in the transmethylation of homocysteine to methio-
nine. A common 677C->T transition in the MTHFR gene
results in a thermolabile variant with decreased enzymatic
activity. Homozygosity for the MTHFR C677T mutation
has been associated with an increase in blood clotting
together with plasma homocysteine increase and DVT
occurrence risk [11].
The aim of this work is to study the role of mutation of fac-
tor V Leiden, prothrombin (factor II) G20210A and MTHFR
C677T genes in patients with pulmonary embolism.Patients and methods
This is a prospective study; it was carried out in the hematol-
ogy department, chest department and clinical pathology
department, Ain Shams University hospitals in the period
between 2010 and 2013. Thirty-one patients presented with
pulmonary embolism were included in the study.
The diagnosis of pulmonary embolism was based on a his-
tory of pulmonary embolism, documented clinically by a
thorough clinical examination, and radiographically by
CXR, C.T pulmonary–angiography. The simultaneous
occurrence of DVT was tested radiologically by duplex US,
in addition to careful clinical examination of the lower limbs.
The exclusion criteria included the occurrence of known
conditions associated with highly increased risk of thrombo-
embolism such as: contraceptive pills, hormonal replacement
therapy, heart failure, malignancy, recent major surgery, pro-
longed immobilization, advanced age, etc.
Once the diagnosis of PE was established, FVL (G 1691A),
prothrombin 20210 A, and MTHFR (C677T) were tested in
peripheral venous blood. EDTA-anticoagulated peripheral
blood samples were obtained from patients. Human plasma
was obtained by centrifugation of EDTA samples at 3000g
at 4 C for 15 min.
In testing for factor V Leiden, prothrombin, and methyl-
enetetrahydrofolate reductase mutations, DNA was isolated
using a Magna Pure Automatic Isolation System (Roche
Diagnostics, Indianapolis, IN). The genotyping of factor V
Leiden G1691A, prothrombin G20210A, and methylenetetra-
hydrofolate reductase C677T was performed via real time
polymerase chain reaction, using the ﬂuorescence melting
curve detection analysis according to a Light Cycler System
(Roche Diagnostics, Manheim, Germany). Primers were
obtained from TIB MOLBION, Berlin, Germany.
Study of some genetic predisposition in pulmonary embolism 1041Statistical analysis
Continuous data were presented as mean and SD values.
Categorical results were presented as number of cases and per-
centages. Continuous variables were compared using student’s
t test or ANOVA test. Chi square and Fisher’s exact tests were
used to examine the relationship between categorical variables.
A signiﬁcance level of P< 0.05 was used in all tests. All statis-
tical procedures were carried out using SPSS version 15 for
Windows (SPSS Inc, Chicago, IL, USA).Results
Twenty-two patients out of 31 (71% of patients) showed factor
V Leiden mutation and 15 patients out of 31 (48.4% of
patients) showed mutation in MTHFR C677T gene, while pro-
thrombin 20210A gene mutation presented in 5 patients
(16.1% of patients) as shown in Table 1. Nine patients (29%
of patients) presented with recurrent DVT and 38.7% of
patients showed recurrent pulmonary embolism. Also, 17
patients (54.8% of patients) presented with other thromboses
in addition to pulmonary embolism [sagittal sinus thrombosis
(2 patients), inferior vena cava thrombosis (4 patients), right
atrial thrombosis (one patient), optic vein thrombosis (2
patients), splenic vein thrombosis (2 patients), lateral sinus
thrombosis (one patient), and myocardial infarction (5
patients)].
The incidence of mutations of the FVL & prothrombin
20210A genes showed no signiﬁcant correlation with the age
& sex of the studied patients (either the heterozygous or the
homozygous forms of the mutation, where relevant, or when
the two forms of mutation for each gene were combined into
one category). Similarly, a non signiﬁcant relationship was
noted when the incidence of either form of the MTHFR gene
mutation was correlated to the patients’ sex (P> 0.05) asTable 1 Description of personal, medical and genetic data among
Age (years), Mean ± SD 32.9
Sex Male (n %) 14
Female (n %) 17
Factor V No mutation (n %) 9
Homozygous (n %) 7
Heterozygous (n %) 15
Prothrombin 20210A No mutation (n %) 26
Homozygous (n %) 0
Heterozygous (n %) 5
MTHFR C677T No mutation (n %) 16
Homozygous (n %) 2
Heterozygous (n %) 13
DVT None 7
Single 15
Recurrent attacks 9
Other thromboses Non 14
Present 17
Number of PE attacks Single 19
Multiple 12shown in Tables 2 and 3. The patients’ ages, however, showed
a statistically signiﬁcant correlation with the MTHFR muta-
tion (whether the mutation was in the homozygous or hetero-
zygous forms of inheritance) where the ages were signiﬁcantly
lower (29.6 ± 7.8 years) in those with MTHFR mutation than
in those without (36.1 ± 9 years). Similar results were
obtained when the relation of the patients’ ages and the pres-
ence of either the heterozygous or the homozygous categories
of MTHFR gene mutation was separately evaluated (i.e. both
forms of mutation were detected more in the lower age
groups), but this did not reach any statistical signiﬁcance
(P> 0.05) as shown in Table 4.
There was a signiﬁcant difference between cases with and
cases without factor V Leiden mutation as regards DVT and
other thromboses, as 40% of cases with mutation either homo-
zygous or heterozygous had multiple DVT compared to 0% of
cases without mutation, also 68.2% of cases with mutation had
other thromboses compared to only 22% of cases without
mutation as shown in Table 5.
There was no signiﬁcant difference between cases with or
without MTHFR C677T gene mutation as regards recurrence
of DVT or pulmonary embolism or as regards the presence or
absence of other thromboses as shown in Table 6.
There was no statistical signiﬁcant difference between
cases with or without prothrombin 20210A gene mutation
as regards recurrence of DVT or pulmonary embolism or
as regards the presence or absence of other thromboses as
shown in Table 7.
Thirteen patients out of 31 patients (41.9%) showed double
gene mutation and only one patient presented with mutations
in the three studied genes. Those patients showed a statistical
signiﬁcant difference in the occurrence of other thromboses
in the body (such as right atrial, sagittal sinus and lateral sinus
thrombosis) and signiﬁcant increase in the incidence of recur-
rent pulmonary embolism than the patients with single gene
mutation as shown in Table 8.cases.
Minimum Maximum
7 ±8.96 21.00 50.00
45.2%
54.8%
29.0%
22.6%
48.4%
83.9%
0.0%
16.1%
51.6%
6.5%
41.9%
22.6%
48.4%
29.0%
45.2%
54.8%
61.3%
38.7%
Table 2 Relation between personal data and Factor V mutation.
Factor V gene P Sig
No mutation Homozygous mutation Heterozygous mutation
Age Mean ± SD 35 ± 7.4 30.1 ± 7.5 33.1 ± 10.5 0.575* NS
Sex Male n (%) 3 (33.3) 4 (57.1) 7 (46.7) 0.727** NS
Female n (%) 6 (66.7) 3 (42.9) 8 (53.3)
Factor V gene P Sig
No mutation Mutation
(homozygous &
heterozygous)
Age Mean ± SD 35 7.4 32.1 9.6 0.428* NS
Sex Male n (%) 3 (33.3) 11 (50) 0.456** NS
Female n (%) 6 (66.7) 11 (50)
* Student’s t test.
** Fisher’s exact test.
Table 4 Relation between personal data and MTHFR gene mutation.
MTHFR C677T gene P Sig
No mutation Homozygous mutation Heterozygous mutation
Age Mean ± SD 36.1 ± 9.0 27 ± 4.2 30 ± 8.3 0.114* NS
Sex Male n (%) 8 (50) 1 (50) 5 (38.5) 0.852** NS
Female n (%) 8 (50) 1 (50) 8 (61.5)
MTHFR C677T gene P Sig
No mutation Mutation (Homozygous & heterozygous)
Age Mean ± SD 36.1 ± 9.0 29.6 ± 7.8 0.04*** S
Sex Male n (%) 8 (50) 6 (40) 0.567**** NS
Female n (%) 8 (50) 9 (60)
* ANOVA test.
** Fisher’s exact test.
*** Student’s t test.
**** Chi square test.
Table 3 Relation between personal data and prothrombin 20210A mutation.
Prothrombin 20210A mutation P Sig
No mutation Heterozygous mutation
Age, Mean ± SD 33.3 ± 9.3 31.2 ± 7.4 0.638* NS
Sex Male n (%) 12 (46.2) 2 (40) 1.0** NS
Female n (%) 14 (53.8) 3 (60)
* Student’s t test.
** Fisher’s exact test.
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There is an increasing recognition of genetic deﬁciencies under-
lying pulmonary embolism in some individuals, particularly
those with early onset of disease, unusual sites of venous
thrombosis and recurrent disease [12].
In the current study 17 patients out of 31 patients were
females (54.8%) and 14 patients were males (45.2%), their
age ranged between 21 and 50 years with the mean age
32.97 years±8.96.This agreed with Alison et al. [13] who reported that sex
hormones alter procoagulant protein levels, platelet function,
and the vessel wall in a manner that may translate into
sex-based differences in thrombosis.
Turan et al. [14], studied inherited thrombophilias in ninety
cases of pulmonary embolism between 2006 and 2009. They
investigated mutations of factor V Leiden, prothrombin
G20210A, MTHFR C677T, the serum levels of antithrombin
III, protein C, protein S, factor VIII and activated protein C
resistance. They found that out of 90 patients, forty-two were
Table 5 Relation between medical data and Factor V gene mutation.
FVL mutation P Sig
No mutation Homozygous Heterozygous
n (%) n (%) n (%)
DVT None 2 (22.2) 3 (42.9) 2 (13.3) 0.062** NS
Single 7 (77.8) 2 (28.6) 6 (40.0)
Recurrent 0 (0.0) 2 (28.6) 7 (46.7)
Other thromboses No 7 (77.8) 2 (28.6) 5 (33.3) 0.089 NS
Yes 2 (22.2) 5 (71.4) 10 (66.7)
Number of PE attacks Single 6 (66.7) 4 (57.1) 9 (60) 1.00** NS
Multiple 3 (33.3) 3 (42.9) 6 (40)
FVL mutation P Sig
No mutation Mutation
n (%) n (%)
DVT None 2 (22.2) 5 (22.7) 0.043** S
Single 7 (77.8) 8 (36.4)
Recurrent 0 (0.0) 9 (40.9)
Other thromboses No 7 (77.8) 7 (31.8) 0.044** S
Yes 2 (22.2) 15 (68.2)
Number of PE attacks Single 6 (66.7) 13 (59.1) 1.0** NS
Multiple 3 (33.3) 9 (40.9)
** Fisher’s exact test.
Table 6 Relation between medical data and MTHFR C677T mutation.
MTHFR mutation P Sig
No mutation Homozygous Heterozygous
n (%) n (%) n (%)
DVT None 4 (25) 0 (0.0) 3 (23.1) 0.969* NS
Single 7 (43.8) 1 (50) 7 (53.8)
Recurrent 5 (31.3) 1 (50) 3 (23.1)
Other thromboses No 8 (50) 1 (50) 5 (38.5) 0.852* NS
Yes 8 (50) 1 (50) 8 (61.6)
Number of PE attacks Single 12 (75) 1 (50) 6 (46.2) 0.260* NS
Multiple 4 (25) 1 (50) 7 (53.8)
MTHFR C677T mutation P Sig
No mutation Mutation
n (%) n (%)
DVT None 4 (25) 3 (20) 1.0* NS
Single 7 (43.8) 8 (53.3)
Recurrent 5 (31.3) 4 (26.7)
Other thromboses No 8 (50) 6 (40) 0.576** NS
Yes 8 (50) 9 (60)
Number of PE attacks Single 12 (75) 7 (46.7) 0.106** NS
Multiple 4 (25) 8 (53.3)
* Fisher’s exact test.
** Chi square test.
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with our results .They also found that patients had a mean
age of 62.6 ± 13.4 years which disagree with our results. This
could be explained as they chose their patients without exclu-
sion criteria whereas, in the current study patients with knownrisk factor for pulmonary embolism including advanced age
were excluded from the study.
In the present study factor V Leiden showed heterozy-
gous mutation in 15 patients (48.4%) and showed homozy-
gous mutation in 7 patients (22.6%) with a total of 22
Table 7 Relation between medical data and prothrombin 20210A gene mutation.
Prothrombin 20210A mutation P Sig
No mutation Heterozygous mutation
n (%) n (%)
DVT None 6 (23.1) 1 (20) 0.831* NS
Single 13 (50) 2 (40)
Recurrent 7 (26.1) 2 (40)
Other thromboses No 13 (50) 1 (20) 0.344* NS
Yes 13 (50) 4 (80)
Number of PE attacks Single 16 (61.5) 3 (60) 1.00* NS
Multiple 10 (38.5) 2 (40)
* Fisher’s exact test.
Table 8 Comparison between cases with single mutation and cases with double/multiple mutation as regards medical data.
Gene mutations P Sig
Single mutation Double/multiple mutations
n (%) n (%)
DVT None 1 (7.7) 4 (28.6) 0.362** NS
Single 8 (61.5) 5 (35.7)
Recurrent 4 (30.8) 5 (35.7)
Other thromboses No 8 (61.5) 3 (21.4) 0.034* S
Yes 5 (38.5) 11 (78.6)
Number of PE attacks Single 11 (84.6) 6 (42.9) 0.046** S
Multiple 2 (15.4) 8 (57.1)
* Chi-square test.
** Fisher’s exact test.
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investigated factor V prevalence in Tunisian patients pre-
sented with thrombosis and found similar results.
In the current study prothrombin 20210A gene showed het-
erozygous mutation in 5 patients (16.1%) and no cases showed
homozygous mutation. This agrees with Bosler et al. [16] who
conﬁrmed the same results and concluded that the prothrom-
bin G20210A mutation is a weak but consistent risk factor
for VTEs and that homozygous G20210A mutation is rare,
with 70 cases reported throughout the literature.
As regards MTHFR C677T, it showed heterozygous muta-
tion in 13 patients (41.9%) and two patients (6.5%) showed
homozygous mutation. These results were similar to the results
of Nicholas et al. [17] who also reported that heterozygote
MTHFR is more common than homozygote one.
Another study [18] investigated the prevalence of factor
V Leiden, prothrombin 20210A and MTHFR C677T
mutations in Romanian patients with deep venous thrombosis
and found that among 144 subjects enrolled in the study
(72 with conﬁrmed idiopathic DVT of the lower limbs and
72 sex- and age-matched healthy controls), factor V Leiden
was detected in 13.88% patients with DVT and 2.77% of con-
trols and prothrombin G20210A mutation was equally distrib-
uted in DVT patients and controls, 2.77%. While MTHFR
C677T gene mutation presented the highest prevalence, com-
prising 58.97% in DVT and 44% in controls.On the other hand, Kruse and co-workers [19] studied the
frequency of thrombophilia-related genetic variations in
patients with idiopathic pulmonary embolism and stated that
the frequency of either the factor V Leiden or prothrombin
mutation was not increased in idiopathic PE patients com-
pared with non idiopathic PE patients or patients who had
pulmonary embolism excluded.
As regards genetic mutation we found that factor V muta-
tion is the most common one followed by MTHFR and pro-
thrombin 20210A mutation is rare which was also observed
by other studies [14,19]. Also, other study [20] reported that
factor V Leiden is the most common inherited form of
inherited thrombophilia, accounting for 40–50% of cases.
In the current study nine patients (29% of patients) pre-
sented with recurrent DVT, 15 patients (48.4%) showed single
attack of DVT and 12 patients (38.7%) showed recurrent
pulmonary embolism. Also, 17 patients (54.8% of patients)
presented with other thromboses in addition to pulmonary
embolism (such as: sagittal sinus thrombosis, inferior vena
cava and right atrial thrombosis, optic vein thrombosis and
splenic vein thrombosis).
Many studies agreed with the current results [18,21] and
revealed similar results specially as regards DVT.
In another study [22] they revealed that high prevalence of
factor V Leiden was found in patients under 45 years of age
(39.3%) as well as in patients with recurrent incidence
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patients with PE combined with deep venous thrombosis in
comparison with patients with isolated PE.
In the present work there was a signiﬁcant difference
between cases with and cases without factor V Leiden muta-
tion as regards DVT and other thromboses, as 40% of cases
with mutation either homozygous or heterozygous had recur-
rent DVT compared to 0% of cases without mutation, also
68.2% of cases with mutation had other thromboses compared
to only 22% of cases without mutation. While cases with or
without mutations in prothrombin G20210A or MTHFR
C677T showed no signiﬁcant difference in the recurrence of
DVT or the presence of other thromboses.
This coincided with other investigator [23] who stated that
factor V Leiden is a genetic disorder characterized by a poor
anticoagulant response to activated Protein C and an increased
risk of venous thromboembolism. Deep venous thrombosis
and pulmonary embolism are the most common manifesta-
tions, but thrombosis in unusual locations also occurs.
In the current work thirteen patients out of 31 patients
(41.9%) showed double gene mutations and only one patient
presented with mutations in the three studied genes. Those
patients showed a statistical signiﬁcant increase in the occur-
rence of other thromboses in the body (such as right atrial, sag-
ittal sinus, lateral sinus thrombosis, etc.) and signiﬁcant
increase in the incidence of recurrent pulmonary embolism
than the patients with single gene mutation. However, those
patients showed no signiﬁcant difference in the incidence or
recurrence of DVT.
This was in consistent with another study [18] which
reported that patients carrying two genetic mutations pre-
sented a 3.7-fold higher thrombotic risk. This corresponds to
46.59% increase in risk comparatively to the presence of only
one genetic factor.
It also agreed with another study [24] which stated that
individuals with two defects have a higher risk of thrombosis
than family members with a single defect. In a pooled analysis
of eight case-control studies, individuals with a single factor V
Leiden or prothrombin G20210A allele had a 5-fold and 4-fold
increase in thrombotic risk, respectively. In contrast, individu-
als doubly heterozygous for both mutations had a 20-fold
increase in relative risk, illustrating the multiplicative effect
of these two mutations on an overall thrombotic risk.
Similar data were revealed by other investigators [25] who
reported that individuals doubly heterozygous for both factor
V Leiden and the prothrombin G20210A mutation have a 3- to
9-fold higher risk of recurrence than those with neither muta-
tion and a 3-fold higher risk than individuals heterozygous for
factor V Leiden alone.
In conclusion
FVL mutations, prothrombin 20210A & MTHFR muta-
tions proved to play an important role in the development of
pulmonary embolism that might be accompanied by other
thromboses elsewhere, DVT or the patients might be at risk
of recurrence of PE attacks. This necessitates testing for the
gene mutations, especially that for the FVL, in young patients
who present with venous thrombo-embolism, thrombosis in
unusual sites or with recurrent thrombo-embolic
manifestations.
Decisions regarding the duration of anticoagulation may be
affected by the genetic proﬁle of the patients for example long-
term anticoagulation is recommended for individuals withhomozygous factor V Leiden or with multiple thrombophilic
disorders. In these individuals at high risk of recurrence, the
potential beneﬁts from long-term warfarin may outweigh the
bleeding risks.
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